Profile data is unavailable for this security.
About the company
Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies. The Company uses both targeted, immuno-oncology, and other approaches to address a range of cancer indications, such as acute myeloid leukemia, lung cancer, brain cancer, and other solid tumors. The product candidates in its pipeline are categorized into three groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumour inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Its advanced product candidate is vebreltinib (APL-101), a potent, oral active, highly selective c-Met inhibitor. Its anti-cancer enhancer product candidates include uproleselan (APL-106) and are antagonists of a cell adhesion receptor called E-selectin. Its immuno-oncology product candidates consist of APL-501, APL-502, APL-801 and APL-810. Its other product candidates include APL-122, APL-102, and APL-108.
- Revenue in USD (TTM)0.00
- Net income in USD-388.09m
- Incorporated2015
- Employees--
- LocationApollomics Inc989 East Hillsdale Blvd, Ste 220FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 209-4055
- Websitehttps://www.apollomicsinc.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NanoViricides Inc | 0.00 | -9.51m | 22.68m | 7.00 | -- | 2.13 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 22.71m | 255.00 | -- | 0.1449 | -- | 9.12 | -1.31 | -1.31 | 0.034 | 2.12 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 22.73m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Trinity Biotech plc (ADR) | 56.71m | -33.88m | 22.81m | 380.00 | -- | -- | -- | 0.4023 | -4.42 | -2.81 | 7.41 | -14.96 | 0.625 | 1.69 | 3.67 | 149,229.00 | -37.34 | -20.30 | -47.55 | -29.54 | 34.21 | 39.92 | -59.75 | -29.86 | 1.03 | -1.96 | 1.36 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 23.17m | 40.00 | -- | 4.12 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.72m | -22.86m | 23.26m | 36.00 | -- | 0.7123 | -- | 13.52 | -0.8222 | -0.8222 | 0.0619 | 1.17 | 0.0387 | -- | 0.5154 | 47,777.78 | -51.40 | -31.60 | -57.29 | -35.49 | -- | -- | -1,329.13 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Gain Therapeutics Inc | 0.00 | -21.14m | 23.29m | 29.00 | -- | 2.69 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 23.59m | 19.00 | -- | 0.9832 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 23.76m | 27.00 | -- | 1.04 | -- | 20.65 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Apollomics Inc | 0.00 | -388.09m | 23.91m | -- | -- | 0.3534 | -- | -- | -4.34 | -4.34 | 0.00 | 0.6225 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,391.69 | 0.012 | -- | -- | -- | -154.03 | -- | -- | -- |
| Equillium Inc | 37.89m | -12.13m | 24.00m | 44.00 | -- | 1.14 | -- | 0.6333 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 24.00m | 1.00 | -- | 0.134 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Medicine Man Technologies Inc | -100.00bn | -100.00bn | 24.20m | 729.00 | -- | 0.3238 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -8.33 | -- | -9.85 | -- | 45.57 | -- | -15.71 | 0.2457 | -- | 0.6059 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 24.31m | 298.00 | -- | 0.5681 | -- | 0.5231 | -1.09 | -1.09 | 6.50 | 5.98 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Biora Therapeutics Inc | 544.00k | -111.08m | 24.77m | 58.00 | -- | -- | -- | 45.53 | -7.13 | -7.12 | 0.0267 | -3.29 | 0.0143 | -- | 0.6594 | 9,379.31 | -291.43 | -122.84 | -482,965.20 | -369.01 | -- | -- | -20,419.48 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
Data as of Jun 25 2024. Currency figures normalised to Apollomics Inc's reporting currency: US Dollar USD
0.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Exchange Traded Concepts LLCas of 31 Mar 2024 | 387.61k | 0.43% |
| Powell Investment Advisors LLCas of 31 Mar 2024 | 130.30k | 0.15% |
| Geode Capital Management LLCas of 31 Mar 2024 | 57.22k | 0.06% |
| Bensler LLCas of 31 Mar 2024 | 25.09k | 0.03% |
| George Kaiser Family Foundationas of 31 Mar 2024 | 24.98k | 0.03% |
| Commonwealth Equity Services LLCas of 31 Mar 2024 | 20.00k | 0.02% |
| Jane Street Capital LLCas of 31 Mar 2024 | 19.07k | 0.02% |
| Warberg Asset Management LLCas of 31 Mar 2024 | 10.03k | 0.01% |
| UBS Securities LLCas of 31 Mar 2024 | 7.51k | 0.01% |
| Korea Investment Management Co., Ltd.as of 05 Jun 2024 | 1.16k | 0.00% |
More ▼
Data from 31 Mar 2024 - 20 Jun 2024Source: FactSet Research Systems Inc.
